AstraZeneca plc stock (GB0009895292): LSE shares edge higher after CARES Phase III update

AstraZeneca shares on the London Stock Exchange traded slightly higher after the company reported positive topline Phase III CARES data for its rare-disease candidate anselamimab, while analyst sentiment on the FTSE 100 pharma name remains broadly constructive.

AstraZeneca shares on the London Stock Exchange traded modestly higher on 05/29/2026, with the stock quoted around 13,760.00p to 13,764.00p and up roughly 0.48% on the day, according to AJ Bell as of 05/29/2026, keeping the United Kingdom-based pharma group among the larger movers in the FTSE 100 healthcare space.AJ Bell as of 05/29/2026

The latest trading session followed AstraZeneca's release on 05/29/2026 of topline results from the global CARES Phase III clinical program, which showed that treatment with the investigational therapy anselamimab led to nominally significant improvements in patients, according to a company communication cited in recent coverage.Insider Monkey citing AstraZeneca data as of 05/29/2026 The update adds another potential rare-disease asset to AstraZeneca's late-stage pipeline, a key area of focus for the United Kingdom group.

The stock, which trades under ticker AZN on the London Stock Exchange, has seen a one-year change of about 28.8% with a 52-week range between roughly 10,104.0p and 15,730.0p, highlighting how the United Kingdom blue chip has participated in the broader strength of large-cap pharmaceuticals over the past year.Investing.com as of 05/29/2026 In Germany, AstraZeneca is also tradable on venues such as Tradegate, where many retail investors follow the London pricing in euro terms.

The CARES program update on 05/29/2026 did not come with immediate financial guidance changes, but it underscores AstraZeneca's strategy of expanding in specialty and rare-disease indications in addition to its established oncology and cardiovascular portfolios, which investors in the United Kingdom market often see as key growth drivers.

As of: 01.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: AstraZeneca plc
• Sector/industry: Pharmaceuticals and biotechnology
• Headquarters/country: Cambridge, United Kingdom
• Core markets: United States, Europe, Asia-Pacific
• Key revenue drivers: Oncology therapies, cardiovascular and renal medicines, respiratory treatments, vaccines and immune therapies
• Home exchange/listing venue: London Stock Exchange (AZN)
• Trading currency: GBP

AstraZeneca plc: core business model

AstraZeneca focuses on discovering and commercializing prescription medicines across oncology, cardiovascular and renal, respiratory, and rare-disease categories, with growth increasingly tied to its portfolio of targeted therapies and biologics.

What banks and research houses say about AstraZeneca plc

According to MarketBeat data as of 05/29/2026, AstraZeneca carries a consensus rating of "Moderate Buy" based on the views of six analysts, with an average 12-month price target of £153.33 compared with a contemporaneous share price of about £138.02.MarketBeat as of 05/29/2026 The same data set shows individual price targets ranging from £115 at the low end to £180 at the high end, indicating a spread of opinion on how quickly the pipeline and existing franchises can translate into earnings growth.

The consensus framework suggests that, at least among the sample tracked by MarketBeat, the London-listed pharma name is still viewed positively following the CARES Phase III update, even as analysts balance late-stage pipeline progress against patent expiries and competitive dynamics in key categories such as oncology and respiratory care.MarketBeat as of 05/29/2026

Conclusion

The modest gain in AstraZeneca's London-listed shares around 05/29/2026 came as investors digested positive topline results from the CARES Phase III trial of anselamimab, reinforcing the emphasis on rare diseases in the company's late-stage pipeline. With a "Moderate Buy" consensus and an average price target of £153.33 as of 05/29/2026, analyst expectations continue to factor in contributions from new therapies alongside established oncology and cardiovascular franchises. For retail investors following the FTSE 100 healthcare name on the London Stock Exchange or via German trading venues, the balance between pipeline progress, competitive pressures and valuation remains a central theme in how the story evolves.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.